Biocon Biologics announces new dermatology data to be presented at EADV Congress 2024
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
It is the first autotaxin inhibitor to be investigated in cancer patients
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
Multi-ethnic innovation helps all complexions appear clearer and more uniform
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
The campus in Genome Valley will provide services in discovery chemistry & discovery biology, safety toxicology, bioanalytical services and formulation development to global pharmaceutical companies
Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
Subscribe To Our Newsletter & Stay Updated